---
figid: PMC5896702__onco12334-fig-0002
figlink: /pmc/articles/PMC5896702/figure/onco12334-fig-0002/
number: F2
caption: 'Biomarkers of resistance to immunotherapy. Tumor cells can evade T‐cell
  attack after immunotherapy via primary or acquired mechanisms of resistance. Potential
  biomarkers of primary resistance include the following: negative PD‐L1 expression
  (A); low neoantigen or mutation load (B); MMR proficiency leading to decreased neoantigens
  (C); low levels of TILs in the tumor parenchyma (D); increased frequency of circulating
  MDSCs (E); decreased levels of IDO (F); deleterious mutations in the IFN‐γ pathway,
  including in the IFNGR (G); loss of function mutations in JAK 1/2 (H); amplification
  of MDM2 (I); and increased VEGF signaling (J). Acquired resistance biomarkers include
  the following: loss of MHC I molecules, leading to inability of T cells to recognize
  neoantigens via the TCR (K); acquired mutations in JAK 1/2 (L); loss of immunodominant
  neoantigens (M); and upregulation of suppressors such as TIM‐3 or LAG‐3 (N). Biomarkers
  can be based on decreased or loss of function (red Xs) or may be upregulated during
  resistance (red upward arrows).Abbreviations: APC, antigen‐presenting cell; CTLA‐4,
  cytotoxic T‐lymphocyte‐associated protein 4; IDO, indoleamine 2,3‐dioxygenase; IFN‐γ,
  interferon‐γ; IFNGR, interferon‐γ receptor; JAK 1/2, Janus kinase 1 and 2; LAG‐3,
  lymphocyte‐activation gene‐3; MDM2, murine double minute 2; MDSC, myeloid‐derived
  suppressor cell; MHC I, major histocompatibility class I; MMR, mismatch repair;
  PD‐1, 2programmed cell death protein 1; PD‐L1, programmed cell death ligand 1; STING,
  stimulator of interferon genes; TCR, T‐cell receptor; TIL, tumor‐infiltrating lymphocyte;
  TIM‐3, T‐cell immunoglobulin mucin‐3; VEGF, vascular endothelial growth factor.'
pmcid: PMC5896702
papertitle: 'Molecular Biomarkers of Primary and Acquired Resistance to T‐Cell‐Mediated
  Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.'
reftext: Young Kwang Chae, et al. Oncologist. 2018 Apr;23(4):410-421.
pmc_ranked_result_index: '159685'
pathway_score: 0.9753603
filename: onco12334-fig-0002.jpg
figtitle: Biomarkers of resistance to immunotherapy
year: '2018'
organisms: Homo sapiens
ndex: d6765dee-dec0-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5896702__onco12334-fig-0002.html
  '@type': Dataset
  description: 'Biomarkers of resistance to immunotherapy. Tumor cells can evade T‐cell
    attack after immunotherapy via primary or acquired mechanisms of resistance. Potential
    biomarkers of primary resistance include the following: negative PD‐L1 expression
    (A); low neoantigen or mutation load (B); MMR proficiency leading to decreased
    neoantigens (C); low levels of TILs in the tumor parenchyma (D); increased frequency
    of circulating MDSCs (E); decreased levels of IDO (F); deleterious mutations in
    the IFN‐γ pathway, including in the IFNGR (G); loss of function mutations in JAK
    1/2 (H); amplification of MDM2 (I); and increased VEGF signaling (J). Acquired
    resistance biomarkers include the following: loss of MHC I molecules, leading
    to inability of T cells to recognize neoantigens via the TCR (K); acquired mutations
    in JAK 1/2 (L); loss of immunodominant neoantigens (M); and upregulation of suppressors
    such as TIM‐3 or LAG‐3 (N). Biomarkers can be based on decreased or loss of function
    (red Xs) or may be upregulated during resistance (red upward arrows).Abbreviations:
    APC, antigen‐presenting cell; CTLA‐4, cytotoxic T‐lymphocyte‐associated protein
    4; IDO, indoleamine 2,3‐dioxygenase; IFN‐γ, interferon‐γ; IFNGR, interferon‐γ
    receptor; JAK 1/2, Janus kinase 1 and 2; LAG‐3, lymphocyte‐activation gene‐3;
    MDM2, murine double minute 2; MDSC, myeloid‐derived suppressor cell; MHC I, major
    histocompatibility class I; MMR, mismatch repair; PD‐1, 2programmed cell death
    protein 1; PD‐L1, programmed cell death ligand 1; STING, stimulator of interferon
    genes; TCR, T‐cell receptor; TIL, tumor‐infiltrating lymphocyte; TIM‐3, T‐cell
    immunoglobulin mucin‐3; VEGF, vascular endothelial growth factor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IFNGR1
  - IFNA1
  - HAVCR2
  - CTLA4
  - IDO1
  - JAK2
  - CD86
  - JAK1
  - CD274
  - TRG
  - VEGFD
  - TRA
  - TRB
  - TRD
  - CD80
  - MDM2
  - PDCD1
  - VEGFC
  - LAG3
  - APC
  - VEGFA
  - VEGFB
  - PGF
  - TMEM173
  - ARS
genes:
- word: IFNGR
  symbol: IFNGR
  source: hgnc_prev_symbol
  hgnc_symbol: IFNGR1
  entrez: '3459'
- word: IFN
  symbol: IFN
  source: hgnc_alias_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: TIM-3
  symbol: Tim-3
  source: hgnc_alias_symbol
  hgnc_symbol: HAVCR2
  entrez: '84868'
- word: CTLA-4
  symbol: CTLA4
  source: hgnc_symbol
  hgnc_symbol: CTLA4
  entrez: '1493'
- word: IDO
  symbol: IDO
  source: hgnc_prev_symbol
  hgnc_symbol: IDO1
  entrez: '3620'
- word: JAK1/2
  symbol: JAK2
  source: hgnc_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: CD86
  symbol: CD86
  source: hgnc_symbol
  hgnc_symbol: CD86
  entrez: '942'
- word: JAK1/2
  symbol: JAK1
  source: hgnc_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: CD80/
  symbol: CD80
  source: hgnc_symbol
  hgnc_symbol: CD80
  entrez: '941'
- word: MDM2
  symbol: MDM2
  source: hgnc_symbol
  hgnc_symbol: MDM2
  entrez: '4193'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: LAG-3
  symbol: LAG3
  source: hgnc_symbol
  hgnc_symbol: LAG3
  entrez: '3902'
- word: APC
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: STING
  symbol: STING
  source: hgnc_alias_symbol
  hgnc_symbol: TMEM173
  entrez: '340061'
chemicals: []
diseases:
- word: ARS
  source: OMIM
  identifier: '616459'
figid_alias: PMC5896702__F2
redirect_from: /figures/PMC5896702__F2
figtype: Figure
---
